![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SERONO TO DEVELOP GENMAB CANCER ANTIBODY HUMAX-CD4; DEAL WORTH UP TO 215 MLN USD
SERONO TO DEVELOP GENMAB CANCER ANTIBODY HUMAX-CD4; DEAL WORTH UP TO 215 MLN USD
Genmab AS said it granted Serono SA worldwide rights to develop and market its HuMax-CD4 antibody for treatment of T-cell lymphomas, in a deal worth an initial 70 mln usd. The antibody, which has been granted fast track status by the US Food and Drug Administration, is currently being evaluated in a Phase III clinical trial. Under the terms of the agreement, Genmab will receive a license fee of 20 mln usd and Serono will also invest 50 mln usd in Genmab common stock, at a premium to the market price.
Forbes (http://www.forbes.com/business/feeds/afx/2005/08/18/afx2184347.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct